TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03219814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Body Project
Description: The Body Project is a dissonance-based body-acceptance program designed to help high school girls and college-age women resist cultural pressures to conform to the appearance ideal standard of female beauty and reduce their pursuit of unrealistic bodies. The Body Project is supported by more research than any other body image program and has been found to reduce onset of eating disorders.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediapsychoeducation
Description: Mediapsychoeducation is used to educate individuals on psychological issues through the use of various medias, in this study mediapsychoeducation is being used to educate individuals on eating disorders and the thin ideal.
Study: NCT01056237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-target therapy
Description: Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 1.0-2.0mg/kg/d
Study: NCT01288196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: A single 30-minute IV infusion of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 1 mg/kg IV
Description: A single 30-minute IV infusion of CNTO 6785 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 3 mg/kg IV
Description: A single 30-minute IV infusion of CNTO 6785 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 10 mg/kg IV
Description: A single 30-minute IV infusion of CNTO 6785 10 mg/kg
Study: NCT00739024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: 8 mg tablet, oral, once daily
Study: NCT01288196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 SC
Description: A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: A single SC dose of placebo administered in up to 3 SC injections
Study: NCT04453449

Intervention type: DRUG
Intervention: Midazolam
Description: Midazolam given as a sedative during diagnostic lumbar medial branch block
Study: NCT02363738

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
Study: NCT02158325

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior capsulorhexis sizes
Description: Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0\~3.9, 4.0\~5.0, 5.1\~6.0 mm in diameter)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior capsulorhexis sizes
Description: Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0\~3.9, 4.0\~5.0, 5.1\~6.0 mm in diameter)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior capsulorhexis sizes
Description: Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0\~3.9, 4.0\~5.0, 5.1\~6.0 mm in diameter)
Study: NCT00739024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, oral, once daily
Study: NCT04411459

Intervention type: OTHER
Intervention: Invasive mechanical ventilation
Description: Invasive mechanical ventilation for respiratory failure associated to COVID-19 pneumonia
Study: NCT01736410

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab, TS ONE, Cisplatin
Description: The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
Study: NCT02361463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D vision
Description: Laparoscopic simulator training to proficiency under 3D conditions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D vision
Description: Laparoscopic simulator training to proficiency under 2D conditions
Study: NCT02980068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15N Nitrate
Description: 1,000 mg/11.8 mmol, oral, on day one, hour zero

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14N Nitrate
Description: 1,000 mg/11.18 mmol, oral, on day hour, hour zero
Study: NCT03384030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted STMST
Description: Participants are subjected to the adapted STMST to induce emotional sweating.
Study: NCT02678169

Intervention type: DEVICE
Intervention: Penumbra Aspiration System
Description: Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain
Study: NCT03809338

Intervention type: DIAGNOSTIC_TEST
Intervention: amh test
Description: Antral follicle count with ultrasound on the 3rd day of menstruation

Intervention type: DIAGNOSTIC_TEST
Intervention: amh test
Description: Antral follicle count with ultrasound on the 3rd day of menstruation
Study: NCT03661619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
Description: Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
Description: Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
Study: NCT03876743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1-Knee Arthroscopy
Description: Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2-Knee Arthroscopy
Description: Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1-ACL reconstruction
Description: Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2-ACL reconstruction
Description: Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
Study: NCT02122887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peace-Building Intervention Process
Description: The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the Other - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,gift giving, summary of process by group leaders.
Study: NCT03369444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLT180a
Description: FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
Study: NCT03369444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLT180a
Description: FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLT180a
Description: FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLT180a
Description: FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
Study: NCT02333409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
Study: NCT01743365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-5FU-Afatinib
Study: NCT02045628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Investment intervention
Description: Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
Study: NCT03581721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer
Description: The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group
Study: NCT03351374

Intervention type: OTHER
Intervention: Software
Description: multi-module system of web software tools

Intervention type: OTHER
Intervention: Software
Description: multi-module system of web software tools

Intervention type: OTHER
Intervention: Software
Description: multi-module system of web software tools

Intervention type: OTHER
Intervention: Software
Description: multi-module system of web software tools

Intervention type: OTHER
Intervention: Software
Description: multi-module system of web software tools
Study: NCT03595904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-Motivate group
Description: Participants in the e-Motivate group will receive standard clinical care which includes patient navigation (e.g., scheduling and reminders). They will also complete a 20-minute, motivational interviewing informed tablet app in the clinic immediately after they receive a referral for a screening colonoscopy. The tablet app consists of educational videos, interactive exercises (e.g., decisional balance), and personalized feedback (e.g., print summary).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy. In particular, they will receive patient navigation which includes scheduling the colonoscopy appointment, making reminder calls, and providing print materials regarding the bowel prep instructions.
Study: NCT01349075

Intervention type: RADIATION
Intervention: TheraSphere
Description: The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
Study: NCT03558048

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Subjects will have their blood drawn during clinic visits over the course of the study period to measure their serum prostate specific antigen levels.
Study: NCT02423187

Intervention type: OTHER
Intervention: No Intervention
Study: NCT03193164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation
Description: The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decubitus Position with the limbs raised to 20º
Description: The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Decubitus Position with the limbs raised to 20º
Description: The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
Study: NCT03790787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
Study: NCT01993069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar-based Yoga Training
Description: 6 weekly Iyengar-based yoga classes
Study: NCT03882476

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: InSight
Description: Clinical decision support (CDS) system for sepsis detection
Study: NCT03790787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Description: Glucokinase activator currently under development
Study: NCT01738581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor Retraining
Description: For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
Study: NCT00241254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (drug)
Description: IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone (drug)
Description: Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
Study: NCT03687086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program A
Description: Cognitive behavioral therapy type A plus medications prepared in packaging type A.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Program B
Description: Cognitive behavioral therapy type B plus medications in packaging type B.
Study: NCT03046459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNZ132-1-40
Description: pegylated peptide inhibiting IL-2, IL-9 and IL-15
Study: NCT01738581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor Retraining
Description: For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-specific Therapy
Description: A non-specific massage and stretching program directed to the hand, wrist and forearm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-specific Therapy
Description: A non-specific massage and stretching program directed to the hand, wrist and forearm
Study: NCT01623661

Intervention type: OTHER
Group type: OTHER
Intervention: hypertonic saline
Description: hypertonic saline 3.0 % (7 ml/kg)
Study: NCT01614665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Participants receive an initial total daily dose of tacrolimus depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 2 doses in the morning and the evening. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus doses are taken orally twice a day in the morning and evening and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus prolonged release
Description: Participants receive an initial total daily dose of tacrolimus prolonged release depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 1 dose. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus prolonged release doses are taken orally once a day in the morning and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
Study: NCT05001100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: rehabilitation
Study: NCT02218567

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: questionnaire qualilty of life

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychological interview

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychological interview

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychological tests

Intervention type: OTHER
Group type: OTHER
Intervention: Motor evaluation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral evaluation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive tests
Study: NCT04183764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01
Description: Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.
Study: NCT01696422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue 1,2,3,4 (attenuated) vaccine
Description: Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue 1,2,3,4 (attenuated) vaccine
Description: Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TetraVax-DV Vaccine - Admixture TV003
Description: Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Route:subcutaneous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Route:subcutaneous
Study: NCT03556462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Health Education
Description: Parents and children receive sleep health education
Study: NCT01726868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liposorber LA-15 System
Description: Six sessions of blood purification treatment with Liposorber LA-15 System.
Study: NCT01867151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten Free Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Normal Diet
Study: NCT04788758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive G8 screening tool administration training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Questionnaire Administration
Description: Complete G8 screening tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral
Description: Receive referral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies